Financial Data and Key Metrics Changes - Revenue growth for Q4 2025 was 9%, with adjusted EBITDA net of NCI increasing by 10% and adjusted EPS rising by 20% compared to Q4 2024 [6][12] - For the full year 2025, revenue growth was 10%, adjusted EBITDA net of NCI increased by 15%, and adjusted EPS grew by 31% [6][12] - Net income attributable to UHS per diluted share for Q4 2025 was $7.06, with adjusted net income per diluted share at $5.88 [13][14] Business Line Data and Key Metrics Changes - In the acute care segment, same-facility net revenues increased by 6.9% in Q4 2025, with a 5.4% increase in revenue per adjusted admission [14][15] - The behavioral health segment saw same-facility net revenues increase by 7.2%, supported by a 5.6% increase in revenue per adjusted patient day [17] - Acute care same-facility EBITDA grew by 10.4% in Q4 2025, with EBITDA margin improving to 14.8% [16] Market Data and Key Metrics Changes - Acute care volumes were flat, impacted by softness in the Las Vegas market, but excluding this market, volumes would have increased by 1% [13][14] - Behavioral segment headcount grew by 3.1%, with total same-facility labor expense growth at 7.3% per adjusted day [17][18] Company Strategy and Development Direction - The company is focused on expanding inpatient capacity and enhancing outpatient services, with plans for new service locations and behavioral health projects [8][9] - Technology adoption is a priority, with AI being deployed to improve clinical outcomes and operational efficiency [10][11] - The company aims to sustain its leadership position by diversifying service offerings and payer mix in the behavioral health segment [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, citing investments in people, facilities, and technology [12] - For 2026, the company expects revenue between $18.4 billion and $18.8 billion, with adjusted EBITDA net of NCI ranging from $2.64 billion to $2.79 billion [19][20] - The guidance includes assumptions about adverse impacts from health insurance exchange reductions and new California staffing regulations [21][22] Other Important Information - Cash generated from operating activities was $1.9 billion for 2025, down from $2.1 billion in 2024, affected by increased receivables and timing of Medicaid payments [18] - The company repurchased 4.65 million shares for $899 million in 2025, with $1.425 billion of repurchase authorization remaining [19] Q&A Session Summary Question: Guidance for 2026 volume growth and pricing assumptions - Management expects a 3%-4% pricing increase in acute care and 2%-3% in behavioral health, acknowledging a moderation in pricing growth [26][27] Question: Impact of AI on operating performance - Initial AI efforts focus on administrative efficiencies, with potential significant impacts on revenue and margins expected over time [28][29] Question: Acute care volume expectations and Nevada market performance - Surgical volume growth in 2025 was positive but lagged overall volume growth; Nevada's market growth was in line with the acute division despite challenges [34][35] Question: Exchange volume visibility and potential bad debt - A 25%-30% decline in exchange volumes is anticipated, with early reporting likely understating the actual decline [39][40] Question: California staffing requirements impact - New staffing regulations will require a different mix of staff, leading to upfront costs and potential short-term volume disruption [45][46] Question: Behavioral outpatient service demand - Outpatient services currently represent about 10% of behavioral segment revenue, with expectations for continued growth in 2026 [51][52] Question: Medicaid supplemental payment programs approval status - Florida's program is expected to be approved soon, while California's program faces more hurdles [70][71]

Financial Data and Key Metrics Changes - Revenue growth for Q4 2025 was 9%, with adjusted EBITDA net of NCI increasing by 10% and adjusted EPS rising by 20% compared to Q4 2024 [4] - For the full year 2025, revenue growth was 10%, adjusted EBITDA net of NCI increased by 15%, and adjusted EPS grew by 31% [4][10] - Net income attributable to UHS per diluted share for Q4 2025 was $7.06, with adjusted net income per diluted share at $5.88 [10] Business Line Data and Key Metrics Changes - In the acute care segment, same-facility net revenues increased by 6.9% in Q4 2025, with same-facility revenue per adjusted admission rising by 5.4% [11] - The behavioral health segment saw same-facility net revenues increase by 7.2%, supported by a 5.6% increase in same-facility revenue per adjusted patient day [13] - Acute care segment EBITDA margin improved by 50 basis points to 14.8% in Q4 2025, while the full year margin improved by 150 basis points to 15.8% [12] Market Data and Key Metrics Changes - Acute care volumes were flat in Q4 2025, impacted by softness in the Las Vegas market, but excluding this market, volumes would have increased by 1% [11] - The behavioral segment experienced a headcount growth of 3.1% in Q4 2025, with total same-facility labor expense growth at 7.3% per adjusted day [13] Company Strategy and Development Direction - The company is focused on expanding its inpatient capacity and enhancing outpatient services, with plans to open new facilities in 2026 [5][6] - Investments in technology, including AI, are aimed at improving clinical outcomes and operational efficiency [7][8] - The company is pursuing a disciplined approach to managing expenses while expanding its service offerings to maintain its leadership position [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, citing investments in people, facilities, and technology [9] - For 2026, the company expects revenue to range between $18.4 billion and $18.8 billion, representing growth of 6%-8% [16] - The guidance assumes same-facility volume growth of 2%-3% for both segments, although initial quarters may be below this range due to winter storms [17] Other Important Information - The company repurchased 4.65 million shares at a total cost of $899 million in 2025, with $1.425 billion of repurchase authorization remaining [16] - Capital expenditures for 2025 were $1 billion, with a significant portion allocated to new hospital projects [15] Q&A Session Summary Question: Guidance for 2026 volume growth and pricing assumptions - Management expects a 3%-4% pricing increase in acute care and 2%-3% in behavioral health, acknowledging a moderation in pricing compared to previous years [23][24] Question: Impact of AI on operating performance - Initial AI efforts focus on administrative efficiencies, with potential significant impacts on revenue and margins expected over time [25][26] Question: Acute care volumes and market performance - Surgical volumes in 2025 lagged overall growth slightly, with expectations for similar trends in 2026 [30][31] Question: Exchange volume visibility and potential bad debt - Management anticipates a 25%-30% decline in exchange volumes, with visibility on bad debt expected to improve over the coming months [36][39] Question: California behavioral staffing requirements impact - New staffing regulations will require a different mix of staff, leading to upfront costs but potentially lower ongoing costs once fully staffed [41][44] Question: Medicaid supplemental programs approval status - Florida's program is expected to be approved soon, while California's program faces more uncertainty [66][70]

Company Overview - Ardent Health, Inc. is a Nashville-based hospital operator focused on acute care, managing 30 hospitals across six states through a mix of wholly owned and joint venture structures, with the majority of its operations tied to joint ventures where Ardent retains control and economic ownership [2] - The company generates revenue primarily through traditional reimbursement channels such as Medicare, Medicaid, and commercial insurers, with Medicare and private payors making up the majority of its revenue mix, while Medicaid represents only about 10%, limiting exposure to government reimbursement volatility [2] Business Model - A defining feature of Ardent's model is that it does not own its hospital real estate, instead leasing facilities under a long-term triple-net master lease with Ventas that runs through 2035 and carries manageable covenant requirements [3] - The company's modern structure was shaped by Equity Group Investments' acquisition in 2015, which doubled hospital count and revenue by 2020, followed by a $500 million strategic investment from Pure Health in 2022 and an IPO in July 2024 [3] Financial Performance - As of January 13th, Ardent's share was trading at $8.84, with trailing and forward P/E ratios of 5.97 and 5.36 respectively [1] - Ardent remains well-capitalized with $609 million in cash, a favorable debt maturity profile extending largely beyond 2029, and LTM EBITDA of approximately $478 million, implying a 6x EV/EBITDA multiple [4] - Despite facing temporary issues in the third quarter, including elevated payor denials and a one-time change in revenue cycle accounting, admissions and revenue trends remain solid, indicating potential for modest EBITDA growth and a mispricing of the stock relative to normalized earnings power [4] Market Context - Since going public, Ardent's shares have declined roughly 50%, driven by temporary operational challenges, but the fundamentals of the business remain intact [3][4] - The bullish thesis on Ardent Health emphasizes its joint venture model, leased real estate, and disciplined capital allocation, drawing parallels to the successful operational strategies of Tenet Healthcare Corporation [5]

Core Insights - Universal Health Services Inc. reported second-quarter adjusted earnings of $5.35 per share, exceeding the consensus estimate of $4.92 [1] - The company generated sales of $4.28 billion, reflecting a year-over-year increase of 9.6%, surpassing the consensus estimate of $4.24 billion [1] Acute Care Hospitals - Adjusted admissions at acute care hospitals increased by 2.0%, while adjusted patient days rose by 1.1% year over year [2] - Net revenue per adjusted admission increased by 3.8%, and net revenue per adjusted patient day increased by 4.7% [2] - Net revenues from acute care services increased by 7.9% on a same facility basis [3] Behavioral Health Care Facilities - Adjusted admissions at behavioral health care facilities increased by 0.4%, and adjusted patient days increased by 1.2% [4] - Net revenue per adjusted admission rose by 8.6%, while net revenue per adjusted patient day increased by 7.8% [4] - Net revenues from behavioral health care services increased by 8.9% on a same facility basis [4] Company Operations - Universal Health operates 29 inpatient acute care hospitals and 338 inpatient behavioral health facilities, along with 61 outpatient facilities [5] Guidance - The company raised its fiscal year 2025 adjusted earnings guidance to $20.00-$21.00 per share, compared to the previous range of $18.45-$19.95 [6] - Sales guidance for 2025 was narrowed to $17.09 billion-$17.31 billion, against the previous range of $17.02 billion-$17.36 billion [6] - The forecasted adjusted EBITDA for 2025 was revised to approximately $2.46 billion-$2.543 billion, up from the prior range of $2.36 billion-$2.48 billion [6] Analyst Insights - Guggenheim Partners noted that adjusted EBITDA-NCI of $643 million exceeded the consensus estimate of $615 million, but core performance was weaker than expected due to adjustments [7] - Analyst Jason Cassorla indicated that higher 2025 EBITDA could lead to increased share repurchase, with a leverage ratio of 1.9x providing flexibility for returns [8] - Despite a recent ~15% drop in stock price, UHS is trading at historically low valuation levels, with cautious investor sentiment regarding future growth in the behavioral health segment [9]